Severity of AIDS and the response to EPO in uremia.

摘要: Abstract To determine the factors that govern their response to erythropoietin (EPO), we conducted a cross-sectional study of all patients in four outpatient hemodialysis facilities Brooklyn, NY, who had end-stage renal disease (ESRD) and human immunodeficiency virus (HIV) infection were receiving recombinant EPO. We also compared hematocrit EPO requirements these those control group without HIV infection. documented known duration infection, total CD 4 count was measured once. In both groups, weekly for 5 weeks mean value calculated each subject. Transferrin saturation twice Intensity assessed by measuring percent reduction urea serum albumin concentration twice; values Twenty-nine (88%) 33 subjects acquired syndrome. Mean 49 ± 32.5 months (median, 48 months), 143 152.4 cells/mm 3 72 ). 27.4% 4.7% with 27.6% 3.7% controls ( P = 0.69). thrice-weekly dose higher (90 52 U/kg body weight) than (62 36 U/Kg 0.001). Among subjects, direct univariate correlations r 0.43; 0.02), transferrin 0.4; 0.03), but not −0.05; 0.8) or −0.11; 0.55). There an inverse correlation between −0.5; 0.003). Multiple regression analysis showed 0.01) 0.003) after adjustment other factors. relationship 0.0006). conclude ESRD hemodialysis, (hematocrit) is modulated EPO, quantity saturation, severity disease. Hemodialysis infected receive